Generic Clopidogrel: Has Substitution for Brand Name Plavix® Been Effective?

Background: Following the expiration of brand name exclusivity of Plavix® in 2012, generic clopidogrel bisulfate was approved. As a widely prescribed medication with significant inter-patient pharmacokinetic and pharmacodynamic variability, data regarding the impact of switching to generic clopidogr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmacy practice 2022-08, Vol.35 (4), p.536-540
Hauptverfasser: Westphal, Erica S., Aladeen, Traci, Vanini, Denis, Rainka, Michelle, McCadden, Kaitlin, Gengo, Francis M., Bates, Vernice
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 540
container_issue 4
container_start_page 536
container_title Journal of pharmacy practice
container_volume 35
creator Westphal, Erica S.
Aladeen, Traci
Vanini, Denis
Rainka, Michelle
McCadden, Kaitlin
Gengo, Francis M.
Bates, Vernice
description Background: Following the expiration of brand name exclusivity of Plavix® in 2012, generic clopidogrel bisulfate was approved. As a widely prescribed medication with significant inter-patient pharmacokinetic and pharmacodynamic variability, data regarding the impact of switching to generic clopidogrel bisulfate on patients is needed. Objective: The objective of this study was to determine whether generic clopidogrel bisulfate is as efficacious as Plavix® for the inhibition of platelet aggregation. Methods: Patients treated with Plavix® monotherapy (n = 254) or generic clopidogrel bisulfate monotherapy (n = 185) were included in this retrospective review. Confounding factors previously found to affect clopidogrel responsiveness (diabetes, female sex, and smoking) were assessed, as well as medications classified as substrates, inducers, and inhibitors of enzymes involved in clopidogrel metabolism. Whole blood impedance aggregometry was used to measure platelet aggregation in response to adenosine diphosphate. Patients were tested after ≥2 weeks of treatment and designated as non-responders if aggregation response exceeded sensitivity thresholds of 6 ohms of impedance. Results: The introduction of generic clopidogrel bisulfate was associated with a decrease in antiplatelet resistance (44% to 31%, p < 0.01) and decreased mean ohms of resistance (5.06 ± 4.55 to 3.32 ± 4.03, p < 0.01). Prior to analysis of secondary outcomes, 217 patients were eliminated due to antiplatelet usage for longer than 3 years (n = 123 for Plavix® and n = 118 for clopidogrel). There was no statistically significant finding in prevalence of secondary events. Conclusion: Resistance rates to the antiplatelet, clopidogrel are significantly lower since the switch to generic formulations. Further investigation into the impact of variability between clopidogrel bisulfate formulations is needed.
doi_str_mv 10.1177/0897190021997006
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2495400510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0897190021997006</sage_id><sourcerecordid>2495400510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-a7c296e34ef5dc77c07cd3f1b929926a44d3c5d515265b3ebf83df7ee49a8d4b3</originalsourceid><addsrcrecordid>eNp1kL1OwzAUhS0EoqWwMyGPLAE7duKYBdGqtEjlRwLmyLGvq1T5KXZSwUvxEDwZiVoYkJjucL7zSfcgdErJBaVCXJJECioJCamUgpB4Dw1pxGhAJRP7aNjHQZ8P0JH3q57jLDxEA8ZinjAhh-h-BhW4XONJUa9zUy8dFFd4rjx-bjPf5E3b5HWFbe3w2KnK4AdVAn4q1CZ___rEY4AKT60F3eQbuD5GB1YVHk52d4Reb6cvk3mweJzdTW4WgWZMNIESOpQxMA42MloITYQ2zNJMhlKGseLcMB2ZiEZhHGUMMpswYwUAlyoxPGMjdL71rl391oJv0jL3GopCVVC3Pg25jDghESUdSraodrX3Dmy6dnmp3EdKSdqPmP4dsauc7extVoL5Lfys1gHBFvBqCemqbl3Vffu_8Bt1I3lS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2495400510</pqid></control><display><type>article</type><title>Generic Clopidogrel: Has Substitution for Brand Name Plavix® Been Effective?</title><source>Access via SAGE</source><creator>Westphal, Erica S. ; Aladeen, Traci ; Vanini, Denis ; Rainka, Michelle ; McCadden, Kaitlin ; Gengo, Francis M. ; Bates, Vernice</creator><creatorcontrib>Westphal, Erica S. ; Aladeen, Traci ; Vanini, Denis ; Rainka, Michelle ; McCadden, Kaitlin ; Gengo, Francis M. ; Bates, Vernice</creatorcontrib><description>Background: Following the expiration of brand name exclusivity of Plavix® in 2012, generic clopidogrel bisulfate was approved. As a widely prescribed medication with significant inter-patient pharmacokinetic and pharmacodynamic variability, data regarding the impact of switching to generic clopidogrel bisulfate on patients is needed. Objective: The objective of this study was to determine whether generic clopidogrel bisulfate is as efficacious as Plavix® for the inhibition of platelet aggregation. Methods: Patients treated with Plavix® monotherapy (n = 254) or generic clopidogrel bisulfate monotherapy (n = 185) were included in this retrospective review. Confounding factors previously found to affect clopidogrel responsiveness (diabetes, female sex, and smoking) were assessed, as well as medications classified as substrates, inducers, and inhibitors of enzymes involved in clopidogrel metabolism. Whole blood impedance aggregometry was used to measure platelet aggregation in response to adenosine diphosphate. Patients were tested after ≥2 weeks of treatment and designated as non-responders if aggregation response exceeded sensitivity thresholds of 6 ohms of impedance. Results: The introduction of generic clopidogrel bisulfate was associated with a decrease in antiplatelet resistance (44% to 31%, p &lt; 0.01) and decreased mean ohms of resistance (5.06 ± 4.55 to 3.32 ± 4.03, p &lt; 0.01). Prior to analysis of secondary outcomes, 217 patients were eliminated due to antiplatelet usage for longer than 3 years (n = 123 for Plavix® and n = 118 for clopidogrel). There was no statistically significant finding in prevalence of secondary events. Conclusion: Resistance rates to the antiplatelet, clopidogrel are significantly lower since the switch to generic formulations. Further investigation into the impact of variability between clopidogrel bisulfate formulations is needed.</description><identifier>ISSN: 0897-1900</identifier><identifier>EISSN: 1531-1937</identifier><identifier>DOI: 10.1177/0897190021997006</identifier><identifier>PMID: 33648379</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><ispartof>Journal of pharmacy practice, 2022-08, Vol.35 (4), p.536-540</ispartof><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-a7c296e34ef5dc77c07cd3f1b929926a44d3c5d515265b3ebf83df7ee49a8d4b3</citedby><cites>FETCH-LOGICAL-c337t-a7c296e34ef5dc77c07cd3f1b929926a44d3c5d515265b3ebf83df7ee49a8d4b3</cites><orcidid>0000-0003-0702-4913</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0897190021997006$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0897190021997006$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33648379$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Westphal, Erica S.</creatorcontrib><creatorcontrib>Aladeen, Traci</creatorcontrib><creatorcontrib>Vanini, Denis</creatorcontrib><creatorcontrib>Rainka, Michelle</creatorcontrib><creatorcontrib>McCadden, Kaitlin</creatorcontrib><creatorcontrib>Gengo, Francis M.</creatorcontrib><creatorcontrib>Bates, Vernice</creatorcontrib><title>Generic Clopidogrel: Has Substitution for Brand Name Plavix® Been Effective?</title><title>Journal of pharmacy practice</title><addtitle>J Pharm Pract</addtitle><description>Background: Following the expiration of brand name exclusivity of Plavix® in 2012, generic clopidogrel bisulfate was approved. As a widely prescribed medication with significant inter-patient pharmacokinetic and pharmacodynamic variability, data regarding the impact of switching to generic clopidogrel bisulfate on patients is needed. Objective: The objective of this study was to determine whether generic clopidogrel bisulfate is as efficacious as Plavix® for the inhibition of platelet aggregation. Methods: Patients treated with Plavix® monotherapy (n = 254) or generic clopidogrel bisulfate monotherapy (n = 185) were included in this retrospective review. Confounding factors previously found to affect clopidogrel responsiveness (diabetes, female sex, and smoking) were assessed, as well as medications classified as substrates, inducers, and inhibitors of enzymes involved in clopidogrel metabolism. Whole blood impedance aggregometry was used to measure platelet aggregation in response to adenosine diphosphate. Patients were tested after ≥2 weeks of treatment and designated as non-responders if aggregation response exceeded sensitivity thresholds of 6 ohms of impedance. Results: The introduction of generic clopidogrel bisulfate was associated with a decrease in antiplatelet resistance (44% to 31%, p &lt; 0.01) and decreased mean ohms of resistance (5.06 ± 4.55 to 3.32 ± 4.03, p &lt; 0.01). Prior to analysis of secondary outcomes, 217 patients were eliminated due to antiplatelet usage for longer than 3 years (n = 123 for Plavix® and n = 118 for clopidogrel). There was no statistically significant finding in prevalence of secondary events. Conclusion: Resistance rates to the antiplatelet, clopidogrel are significantly lower since the switch to generic formulations. Further investigation into the impact of variability between clopidogrel bisulfate formulations is needed.</description><issn>0897-1900</issn><issn>1531-1937</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kL1OwzAUhS0EoqWwMyGPLAE7duKYBdGqtEjlRwLmyLGvq1T5KXZSwUvxEDwZiVoYkJjucL7zSfcgdErJBaVCXJJECioJCamUgpB4Dw1pxGhAJRP7aNjHQZ8P0JH3q57jLDxEA8ZinjAhh-h-BhW4XONJUa9zUy8dFFd4rjx-bjPf5E3b5HWFbe3w2KnK4AdVAn4q1CZ___rEY4AKT60F3eQbuD5GB1YVHk52d4Reb6cvk3mweJzdTW4WgWZMNIESOpQxMA42MloITYQ2zNJMhlKGseLcMB2ZiEZhHGUMMpswYwUAlyoxPGMjdL71rl391oJv0jL3GopCVVC3Pg25jDghESUdSraodrX3Dmy6dnmp3EdKSdqPmP4dsauc7extVoL5Lfys1gHBFvBqCemqbl3Vffu_8Bt1I3lS</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Westphal, Erica S.</creator><creator>Aladeen, Traci</creator><creator>Vanini, Denis</creator><creator>Rainka, Michelle</creator><creator>McCadden, Kaitlin</creator><creator>Gengo, Francis M.</creator><creator>Bates, Vernice</creator><general>SAGE Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0702-4913</orcidid></search><sort><creationdate>20220801</creationdate><title>Generic Clopidogrel: Has Substitution for Brand Name Plavix® Been Effective?</title><author>Westphal, Erica S. ; Aladeen, Traci ; Vanini, Denis ; Rainka, Michelle ; McCadden, Kaitlin ; Gengo, Francis M. ; Bates, Vernice</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-a7c296e34ef5dc77c07cd3f1b929926a44d3c5d515265b3ebf83df7ee49a8d4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Westphal, Erica S.</creatorcontrib><creatorcontrib>Aladeen, Traci</creatorcontrib><creatorcontrib>Vanini, Denis</creatorcontrib><creatorcontrib>Rainka, Michelle</creatorcontrib><creatorcontrib>McCadden, Kaitlin</creatorcontrib><creatorcontrib>Gengo, Francis M.</creatorcontrib><creatorcontrib>Bates, Vernice</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Westphal, Erica S.</au><au>Aladeen, Traci</au><au>Vanini, Denis</au><au>Rainka, Michelle</au><au>McCadden, Kaitlin</au><au>Gengo, Francis M.</au><au>Bates, Vernice</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Generic Clopidogrel: Has Substitution for Brand Name Plavix® Been Effective?</atitle><jtitle>Journal of pharmacy practice</jtitle><addtitle>J Pharm Pract</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>35</volume><issue>4</issue><spage>536</spage><epage>540</epage><pages>536-540</pages><issn>0897-1900</issn><eissn>1531-1937</eissn><abstract>Background: Following the expiration of brand name exclusivity of Plavix® in 2012, generic clopidogrel bisulfate was approved. As a widely prescribed medication with significant inter-patient pharmacokinetic and pharmacodynamic variability, data regarding the impact of switching to generic clopidogrel bisulfate on patients is needed. Objective: The objective of this study was to determine whether generic clopidogrel bisulfate is as efficacious as Plavix® for the inhibition of platelet aggregation. Methods: Patients treated with Plavix® monotherapy (n = 254) or generic clopidogrel bisulfate monotherapy (n = 185) were included in this retrospective review. Confounding factors previously found to affect clopidogrel responsiveness (diabetes, female sex, and smoking) were assessed, as well as medications classified as substrates, inducers, and inhibitors of enzymes involved in clopidogrel metabolism. Whole blood impedance aggregometry was used to measure platelet aggregation in response to adenosine diphosphate. Patients were tested after ≥2 weeks of treatment and designated as non-responders if aggregation response exceeded sensitivity thresholds of 6 ohms of impedance. Results: The introduction of generic clopidogrel bisulfate was associated with a decrease in antiplatelet resistance (44% to 31%, p &lt; 0.01) and decreased mean ohms of resistance (5.06 ± 4.55 to 3.32 ± 4.03, p &lt; 0.01). Prior to analysis of secondary outcomes, 217 patients were eliminated due to antiplatelet usage for longer than 3 years (n = 123 for Plavix® and n = 118 for clopidogrel). There was no statistically significant finding in prevalence of secondary events. Conclusion: Resistance rates to the antiplatelet, clopidogrel are significantly lower since the switch to generic formulations. Further investigation into the impact of variability between clopidogrel bisulfate formulations is needed.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>33648379</pmid><doi>10.1177/0897190021997006</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-0702-4913</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0897-1900
ispartof Journal of pharmacy practice, 2022-08, Vol.35 (4), p.536-540
issn 0897-1900
1531-1937
language eng
recordid cdi_proquest_miscellaneous_2495400510
source Access via SAGE
title Generic Clopidogrel: Has Substitution for Brand Name Plavix® Been Effective?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A08%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Generic%20Clopidogrel:%20Has%20Substitution%20for%20Brand%20Name%20Plavix%C2%AE%20Been%20Effective?&rft.jtitle=Journal%20of%20pharmacy%20practice&rft.au=Westphal,%20Erica%20S.&rft.date=2022-08-01&rft.volume=35&rft.issue=4&rft.spage=536&rft.epage=540&rft.pages=536-540&rft.issn=0897-1900&rft.eissn=1531-1937&rft_id=info:doi/10.1177/0897190021997006&rft_dat=%3Cproquest_cross%3E2495400510%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2495400510&rft_id=info:pmid/33648379&rft_sage_id=10.1177_0897190021997006&rfr_iscdi=true